Galith Abourbeh
E-mail: abourbehg@hadassah.org.il
CURRICULUM VITAE
Born in Israel – 1973
EDUCATION and Employment
2010 -
 Hadassah
Hebrew
University
Hospital,
Radiochemistry/
Cyclotron/ microPET Unit, Jerusalem, Israel.
Researcher; Pre-clinical project manager in the field of PET molecular
imaging.
2008-2009  Atomic Energy Commission (CEA), Department of Life Sciences
(DSV), Laboratory of Experimental Molecular Imaging (LIME),
Orsay, France.
Post doctoral research under the supervision of Prof. Bertrand Tavitian.
Research project: development of rodent models of experimental
autoimmune encephalomyelitis (EAE) for studying neuroinflammation in
multiple sclerosis using positron emission tomography (PET).
2007
 Hadassah
Hebrew
University
Hospital,
Radiochemistry/
Cyclotron Unit, Jerusalem, Israel.
Researcher; project management in the field of molecular imaging in
PET-Oncology
2002-2006
 Hadassah
Hebrew
University
Hospital,
Radiochemistry/
Cyclotron/Unit, Jerusalem, Israel.
 The Hebrew University of Jerusalem, The Alexander Silberman
Institute of Life Sciences, Department of Biological Chemistry,
Unit of Cellular Signaling, Jerusalem, Israel.
Direct course to Ph.D. in molecular imaging and biochemistry under the
supervision of Prof. Eyal Mishani and Prof. Alexander Levitzki.
Title of Ph.D. thesis: “Exploring Radiolabeled Irreversible Inhibitors of
the Epidermal Growth Factor Receptor (EGFR) as Imaging Agents for
Positron Emission Tomography (PET)”.
2000-2001
The Hebrew University of Jerusalem, Faculty of Medicine, School
of Pharmacy, Jerusalem, Israel.
M.Sc Pharm. degree as part of the direct course to Ph.D.
Magna cum laude
1994-1998
The Hebrew University of Jerusalem, Faculty of Medicine, School
of Pharmacy, Jerusalem, Israel.
B. Pharm. Bachelor degree in Pharmacy.
Summa cum laude.
PUBLICATIONS add titles of papers
1. Mishani E., Abourbeh G., Rozen Y., Jacobson O., Laki D., Ben-David I., Levitzki A.
and Shaul M. 2004, Nucl Med Biol (31), 469-76.
2. Shaul M., Abourbeh G., Jacobson O., Rozen Y., Laki D., Levitzki A. and Mishani E.
2004, Bioorg Med Chem (12), 3421-9.
1
Galith Abourbeh
E-mail: abourbehg@hadassah.org.il
3. Mishani E., Abourbeh G., Jacobson O., Dissoki S., Ben Daniel R., Rozen Y., Shaul
M. and Levitzki A. 2005, J Med Chem (48), 5337-5348.
4. Abourbeh G., Dissoki S., Jacobson O., Litchi A., Ben Daniel R., Laki D., Levitzki A.
and Mishani E. 2007, Nucl Med Biol (34), 55-70.
5. Mishani E. and Abourbeh G. 2007, Curr Top Med Chem (7), 1755-72 (Review)
6. Dissoki S., Aviv Y., Laky D., Abourbeh G., Levizki A. and Mishani E. 2007, Appl
Radiat Isot (65), 1140-51.
7. Mishani E., Abourbeh G., Eiblmaier M. and Anderson C. 2008 Curr Pharm Des
(14), 2983-98.
8. Abourbeh G., Thézé B., Maroy R., Dubois A., Dollé F., Fontyn Y., Brulon V.,
Tavitian B. and Boisgard R. 2012 J Neurosci (32):5728-36.
9. Abourbeh G., Shir A., Mishani E., Ogris M., Rödl W., Wagner E. and Levitzki A.
2012 IUBMB Life (64):324-30.
10. Ilovich O., Abourbeh G., Bocher M., Freedman N., Billauer H., Dotan S.,
Danenberg H.D. and Mishani E. 2012 Mol Imaging Biol (14):625-636.
11. Kesner A.L., Abourbeh G., Mishani E., Chisin R., Tshori S. and Freedman N. 2013
EJNMMI Res. (3):29 ???
12. Jacobson O., Abourbeh G., Tsvirkun D. and Mishani E. 2013 Nucl Med Biol In
Press.
PRESENTATIONS IN SCIENTIFIC MEETINGS
1. Mishani E., Levitzki A., Abourbeh G., Ortu G., Ben-David I., Rozen Y., Lester H.,
Fridman N., Chisin R. Novel irreversible [ 11C]EGFR-TK inhibitors for cancer
imaging diagnosis. The 50th Annual Conference of the Society of Nuclear Medicine
(2003), New Orleans, USA. Lecture
2. Abourbeh G., Boisgard R., Dollé F., Maroy R., Dubois A., Brulon V., Fontyn Y.,
Tavitian B. PET imaging of spinal cord lesions in rat experimental autoimmune
encephalomyelitis using the peripheral benzodiazepine receptor ligand, [ 18F]DPA714. The fourth European Molecular Imaging Meeting (2009), Barcelona,
Spain. Lecture
PATENTS
1. E. Mishani, Y. Rozen, G. Abourbeh and A. Levitzki. Novel EGFR-TK irreversible
inhibitors for cancer therapy, radiotherapy and diagnosis. U.S. Patent No.
7,172,749 (2007).
2. S. Dissoki, G. Abourbeh, A. Levitzki, E. Mishani. Labeled EGFR Irreversible
biomarkers: Anilinoquinazoline-7-[F-18]-PEG derivatives. Applied to U.S. patent
(2006).
3. E. Mishani, H. Billauer, G. Abourbeh, S. Dotan, N.M.T. Freedman, H. Danenberg,
M. Bocher. Ammonium salts for myocardial perfusion imaging. Applied to U.S.
patent (2011).
Grants
2011-2014
Israel Science Foundation (ISF), Carbon-11/ Fluorine-18 labeled
ammonium salts as myocardial perfusion PET imaging agents. Eyal
Mishani (PI), Galith Abourbeh, Haim Danenberg, Moshe Bocher.
2